Predicting mortality in non-cystic fibrosis bronchiectasis patients using distance-saturation product

Chun-Yu Lin\textsuperscript{a,b}, Meng-heng Hsieh\textsuperscript{a,b}, Yueh-Fu Fang\textsuperscript{a,b}, Chien-Wei Peng\textsuperscript{b,c}, Jia-Shiuan Ju\textsuperscript{a,b}, Yu-Lun Lo\textsuperscript{a,b}, Shu-Min Lin\textsuperscript{a,b} and Horng-Chyuan Lin\textsuperscript{a,b,d}

\textsuperscript{a}Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; \textsuperscript{b}College of Medicine Chang Gung University, Taoyuan, Taiwan; \textsuperscript{c}Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; \textsuperscript{d}Department of Respiratory Therapy, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

**ABSTRACT**

**Background:** The bronchiectasis severity index (BSI) and FACED score are currently used in predicting outcomes of non-cystic fibrosis bronchiectasis (NCFB). Distance-saturation product (DSP), the product of distance walked, and lowest oxygen saturation during the 6-min walk test showed strong predictive power of mortality in non-CF bronchiectasis patients. This study aimed to compare the efficacy of these scores and DSP in predicting mortality.

**Methods and Patients:** Our retrospective study included NCFB patients from January 2004 to December 2017. We recorded the basic data, pulmonary function, radiologic studies, sputum culture results, acute exacerbations (AE), emergency department (ED) visits, hospitalization, and mortality.

**Results:** A total 130 NCFB patients were analysed. The mean BSI score, FACED score, and DSP were 8.8 ± 4.9, 3.4 ± 1.7, and 413.1 ± 101.5 m\(^{\circ}\)O\(_2\), respectively. BSI and FACED scores had comparable predictive power for AE (\(p\) = .011; \(p\) = .010, respectively). The BSI score demonstrated a significant correlation with ED visits (\(p\) = .0003). There were 12 deaths. Patients were stratified using a DSP cut-off value of 345 m\(^{\circ}\)O\(_2\) according to the best area under receiver operator characteristic curve (AUC) value in mortality. DSP was not correlated with AE and ED visits. BSI, FACED scores, and DSP demonstrated statistically significant correlations with hospitalization (\(p\) < .0001; \(p\) < .0001; \(p\) = .831). The AUC for overall mortality was similar for BSI, FACED score, and DSP (0.80 versus 0.85, \(p\) = .491; 0.85 versus 0.83, \(p\) = .831).

**Conclusion:** DSP had comparable predictive power for mortality as the well-validated BSI and FACED scores and is relatively easy to use in clinical practice.

**KEY MESSAGE**

- Distance-saturation product (DSP) comprised with the product of distance walked, and lowest oxygen saturation during the 6-min walk test, which is common used in clinical practice.
- DSP demonstrated strong and comparable predictive power of mortality as the well-validated BSI and FACED scores in non-CF bronchiectasis patients.

**Abbreviations:** BSI: bronchiectasis severity index; NCFB: non-cystic fibrosis bronchiectasis; DSP: distance-saturation product; AE: acute exacerbations; ED: emergency department; FEV\(_1\): forced expiratory volume in 1 second; 6MWT: 6-minute walk test; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; BMI: body mass index; 6MWD: 6-minute walk distance; AUC: area under the curve; ROC: receiver operating characteristic; QoL: quality of life

**Introduction**

Non-cystic fibrosis bronchiectasis (NCFB) is a progressively inflammatory, destructive lung disease, characterised by mucus impaction, bronchial dilatation, and recurrent infections [1–3]. There are two validated severity scores for NCFB: the bronchiectasis severity index (BSI) and FACED score [4,5]. Both of them consist of forced expiratory volume in 1 s (FEV\(_1\)), age, chronic colonization of \textit{Pseudomonas aeruginosa}, radiological extension, and dyspnoea [4,5]. As McDonnell et al. reported, the BSI score appears to better predict hospital admission, exacerbation, quality of life, and lung function decline than the FACED score [6]. This may attribute to the addition of body mass index
(BMI), colonization with other microorganisms, hospitalization and exacerbation frequency in BSI score. Nevertheless, in a 19-year cohort, Ellis et al. demonstrated that the FACED score had slightly superior predictive power for 15-year mortality [7]. The BSI and FACED scores are both useful in predicting outcomes of non-CF bronchiectasis, but the complexity of BSI scores limits the use in daily practice.

The 6-min walk test (6MWT) is a useful exercise test to evaluate cardiovascular and pulmonary functional status in many diseases [8–11]. Distance-saturation product (DSP) is the product of distance walked and lowest oxygen saturation during the 6MWT, which is correlated with survival in idiopathic pulmonary fibrosis (IPF) patients [12]. We previously conducted a retrospective study comparing each parameter collected from the 6MWT and showed that DSP had strong predicting power for mortality in NCFB patients [13]. In the Asian context, only Wang et al. conducted a retrospective study with validated BSI and FACED scores involving post-tuberculosis bronchiectasis patients [14]. This study aims to compare the prediction power of BSI, FACED score, and DSP for mortality in NCFB patients.

Methods

Subjects

This retrospective study was conducted from January 2004 to December 2017 at the Linkou Chang Gung Memorial Hospital, Taiwan. All adult patients underwent high-resolution computed tomography, confirming bronchiectasis. Patients were excluded if they had active tuberculosis, cystic fibrosis or malignancy, not performed 6MWT or who was under O2 supplement.

We recorded the following demographic characteristics: age, sex, body mass index (BMI), sputum culture results, pulmonary function, radiographic reports, medications, exacerbations, and mortality. Data for calculating the BSI and FACED scores were taken from the patients’ medical records. For every patient, we cultured at least two sputum samples for Pseudomonas spp. Colonization with P. aeruginosa was defined as ‘the isolation of P. aeruginosa in sputum culture on two or more occasions, at least 3 months apart in a 1-year period’. As we reported previously [15], we defined acute exacerbation (AE) as an event that was clinically diagnosed by the physician and required antibiotic prescription for acute onset of increasing cough, worsening dyspnoea, and changes in sputum characteristics (e.g., volume, consistency, and purulence). We also recorded the frequency of ED visits and hospitalization because of bronchiectasis AE in 2 years. All-cause mortality was ascertained as of December 2017 and dates of death obtained from medical records.

The study was approved by the institutional review board of Chang Gung Memorial Hospital (approval no. 201802305A3). Informed consent was waived because this was a retrospective study and there was no modification in patient management. All personal information was encrypted in a database, and patient data were anonymized. There was no breach of privacy.

6MWT and Pulmonary Function Tests

The 6MWT was performed in accordance with the standard protocol of the American Thoracic Society [11,16] under the supervision of well-trained technicians. All 6MWT were performed with pulse oximetry for continuous recording of oxygen saturation (SpO2). Dyspnoea was assessed using the Borg scale each minute during the 6MWT and maximum dyspnoea level was recorded [17]. Spirometry was performed as per recommendations made by the American Thoracic Society/European Respiratory Society [18]. We excluded 6MWTs performed under oxygen supplement, and all 6MWTs were performed in room air. Variables from 6MWT, including 6-min walk distance (6MWD), and serial oxygen saturation in exercise were recorded. DSP was defined as the product of the final 6MWD in metres and the lowest oxygen saturation in room air during the 6MWT [12,13]. For example, a patient walking a total of 200 m with the lowest oxygen saturation of 88% during 6MWT would have a DSP of 176 m% (e.g. 200 × 0.88).

Categorization

In addition to the calculation of severity scores, disease status also categorised as mild (BSI score ≤4, FACED score ≥2), moderate (BSI score 5–8, FACED score 3–4), and severe (BSI score ≥9, FACED score ≥5) disease according to each scoring system. The patients were stratified using a DSP cut-off value of 345 m% into two groups according to the best area under the curve (AUC) value in predicting mortality.

Statistical Analyses

We used Fisher’s exact test to compare categorical variables and were described using counts (percentages). Parametric data were expressed as means ± standard deviations. Mean differences were
compared using the t-test (or analysis of variance for more than two groups). Non-parametric data were compared using Chi-square test. The receiver operating characteristic (ROC) curves were calculated, and AUC compared using DeLong’s test for two correlated ROC curves, where appropriate, was used to determine the statistical significance of the difference between the means. Optimum threshold values were identified as those yielding the highest Youden’s index (sensitivity + [1 – specificity]) [7]. After identifying the DSP that generated the highest AUC, actuarial survival curves were then constructed for comparison of DSPs above this threshold to those falling below this point. Survival analysis was performed using the Kaplan–Meier method. Kaplan–Meier curves were compared using the log-rank test. In further analyses, the participants were stratified into two groups according to the best AUC value in mortality. Two, eight, and 26 patients had mild, moderate, and severe BSI, respectively, as classified by DSP of ≤ 345 m%. Two, 11, and 23 patients with mild, moderate, and severe FACED scores, respectively, had DSP < 345 m%. DSP was not

data from all 130 adult patients diagnosed with NCFB were analyzed (Figure 1). The median duration of follow-up was 80 months (range, 24–216 months). Patient demographics are shown in Table 1. The mean age of the patients was 66.5 ± 11.9 years. The mean BSI score, FACED score, and DSP were 8.8 ± 4.9, 3.4 ± 1.7, and 413.1 ± 101.5 m% (Table 1). The BSI score
categorised 49% of the patients as severe compared with 28% categorised by the FACED score (Table 2). While BSI and FACED scores had comparable predictions for AE (p=.011; p=.010, respectively, Table 2), BSI showed more significant correlation with ED visit than FACED score (p=.0003; p=.074, respectively, Table 2). The study patients were further stratified using a DSP cut-off value of 345 m% into two groups according to the best AUC value in mortality. Two, eight, and 26 patients had mild, moderate, and severe BSI, respectively, as classified by DSP of < 345 m%. Two, 11, and 23 patients with mild, moderate, and severe FACED scores, respectively, had DSP <345 m%. DSP was not

Figure 1. Flowchart of the study design. BSI: bronchiectasis severity index; DSP: distance-saturation product; NCFB: non-cystic fibrosis bronchiectasis; O2: Oxygen; 6MWT: 6-minute walk test.

Table 1. Clinical characteristics of NCFB patients.

| Variables                                      | All patients n = 130 |
|------------------------------------------------|----------------------|
| Age (years), mean ± SD                         | 66.5 ± 11.9          |
| Male, n (%)                                    | 57 (44)              |
| BMI (kg/m²), mean ± SD                         | 22.7 ± 3.3           |
| Comorbidity                                    |                      |
| Hypertension                                   | 15 (12)              |
| Ischemic heart disease                         | 3 (2)                |
| Diabetes mellitus                              | 11 (8)               |
| Solid tumours                                   | 3 (2)                |
| Liver diseases                                  | 4 (3)                |
| Chronic kidney disease                         | 1 (1)                |
| FEV1, %predicted, mean ± SD                    | 62.3 ± 22.9          |
| Pseudomonas colonization, n (%)                | 39 (30)              |
| mMRC dyspnoea score, mean ± SD                 | 1.9 ± 0.9            |
| Lobes affected, mean ± SD                      | 2.8 ± 1.1            |
| Hospitalizations in last 2 years, mean ± SD    | 1.1 ± 1.8            |
| Exacerbations in previous year, mean ± SD      | 1.3 ± 2.1            |
| BSI, mean ± SD                                 | 8.8 ± 4.9            |
| FACED, mean ± SD                               | 3.4 ± 1.7            |
| DSP, m%, mean ± SD                             | 413.1 ± 101.5        |
| Death, n (%)                                   | 12 (9)               |

SD: standard deviation; BMI: body mass index; mMRC: modified Medical Research Council; BSI: bronchiectasis severity index; DSP: distance-saturation product.

Results

Patients’ characteristics

Data from all 130 adult patients diagnosed with NCFB were analyzed (Figure 1). The median duration of follow-up was 80 months (range, 24–216 months). Patient demographics are shown in Table 1. The mean age of the patients was 66.5 ± 11.9 years. The mean BSI score, FACED score, and DSP were 8.8 ± 4.9, 3.4 ± 1.7, and 413.1 ± 101.5 m% (Table 1). The BSI score
correlated with AE and ED visit. Nevertheless, BSI, FACED scores, and DSP all demonstrated statistically significant correlations with hospitalization ($p < .0001$; $p < .0001$; $p = .0007$, respectively, Table 2, Figure 2).

**Survival analysis**

Of the 130 patients, 12 died (9%) during the study period. Mortality varied according to BSI and FACED scores, from 3% and 0% in mild cases to 16% and 27% for those with severe scores. Using a DSP cut-off value of 345 m%, the mortality was 3% in those with high DSP and was 25% in those with worse DSP ($p<.0001$, Table 3).

Kaplan–Meier survival curves for mortality according to BSI, FACED scores, and DSP are shown in Figure 3. There was little difference between mild and moderate BSI scores ($p=.928$). Severe BSI score had significantly reduced the survival rate (hazard ratio: 6.08, $p=.047$). Regarding the FACED score, mild and moderate cases had no survival difference ($p=.385$). The severe group had significantly reduced survival compared with the mild group (Hazard ratio:5.38, $p = .0128$). Patients who had worse DSP ($<345$ m%) demonstrated lower death rate than those with high DSP ($\geq 345$ m%) (hazard ratio:9.03, $p < .0001$). The results of univariate Cox proportional hazards analysis are shown in Table 3.

**Receiver operating characteristic analysis**

The AUC for overall mortality was similar for BSI, FACED scores, and DSP (0.80 versus 0.85, $p=.491$; 0.85 versus 0.83, $p=.831$, Table 4, Figure 4). The optimum threshold of $>9.5$ for the BSI score yielded a specificity and sensitivity of 61.9% and 83.3%, respectively; for the FACED score, a threshold of $>4.5$ yielded a specificity and sensitivity of 78.0% and 83.3%, respectively;
for the DSP, a threshold of $\geq 345$ m% yielded a specificity and sensitivity of 77.1% and 75%, respectively.

**Discussion**

To the best of our knowledge, this is the first study to evaluate the prognostic value of DSP and compare it with that of the validated BSI and FACED scores in NCFB patients. In the 130 patients with a median follow-up duration of 80 months, both BSI and FACED scores were positively correlated with AE and ED visit and DSP was not. Nevertheless, similar to BSI and FACED score, DSP was strongly associated with hospitalization. Moreover, in the ROC analysis, BSI, FACED score, and DSP had comparable AUCs in predicting mortality.

The BSI and FACED scores are two well-known prognostic indices for bronchiectasis [4,5]. Both comprise age, value of FEV1% predicted, chronic colonization by P. aeruginosa, radiological extension of bronchiectasis, and degree of dyspnoea. BSI also considers BMI, exacerbation frequency, prior hospitalization for exacerbation, and chronic colonization with bacteria other than P. aeruginosa. Both scores classify patients into low-, moderate-, and high-risk groups, using different thresholds. In the UK, Ellis et al. analysed 74 patients with a median follow-up of 18.8 years and demonstrated that the AUC for the 5-year mortality was similar for BSI and FACED scores, although the FACED score was superior to BSI in predicting 15-year mortality [7]. McDonnell et al. conducted an analysis of seven European cohorts when comparing the BSI and FACED score. They found that BSI predicted hospital admissions, exacerbations, quality of life, and lung function decline precisely while both BSI and FACED scores had comparable predicting power for mortality [6]. BSI score appears to have better prediction in hospital admission, exacerbation than the FACED score, this may attribute to the addition of hospitalization and exacerbation frequency in BSI score. Only one retrospective study in Asia, conducted by Wang et al. in China showed that the AUC of the FACED score in predicting 4-year mortality was 0.81 and that of the BSI was 0.70 in post-tuberculosis bronchiectasis patients [14]. In the current research, we found that both BSI and FACED scores were significantly correlated with acute exacerbation, hospitalization, and mortality. The BSI score showed a more significant association with ED visit than the FACED score. Because of clinic visit and hospitalization are relative accessible in Taiwan. This may have overestimated the BSI score and led to some bias.

The 6MWT is a convenient clinical evaluation tool and many variables derived from the 6MWT are useful for evaluating prognosis, including hospitalization and mortality [19,20]. The DSP is a composite measure that

| Subjects, n | Mortality, n (%) | Hazard ratio (95% CI) | p value |
|-------------|------------------|----------------------|---------|
| **BSI**     |                  |                      |         |
| Mild        | 29               | 1 (3)                | Reference |
| Moderate    | 37               | 1 (3)                | 0.88 (0.05–14.14) | .928 |
| Severe      | 64               | 10 (16)              | 6.08 (1.03–11.82) | .047 |
| **FACED**   |                  |                      |         |
| Mild        | 36               | 0 (0)                | Reference |
| Moderate    | 57               | 3 (5)                | 4.05 (0.17–95.39) | .385 |
| Severe      | 37               | 10 (27)              | 5.38 (1.43–20.22) | .0128 |
| **DSP**     |                  |                      |         |
| $\geq 345$  | 94               | 3 (3)                | Reference |
| $<345$      | 36               | 9 (25)               | 9.03 (4.02–54.96) | <.0001 |

BSI: bronchiectasis severity index; DSP: distance-saturation product.

| Mortality | BSI   | FACED | DSP   |
|-----------|-------|-------|-------|
| 0.80 (0.63–0.96) | 0.85 (0.75–0.94) | 0.83 (0.70–0.96) |
| **p** = .491 | **p** = .831 | **p** = .578 |

Data are presented as area under the curve (95% CI). 
*p-values calculated using DeLong’s test for two correlated ROC curves.

Comparison of ROC curves between BSI and FACED; *comparison of ROC curves between FACED and DSP; *comparison of ROC curves between DSP and BSI.

BSI: bronchiectasis severity index; DSP: distance-saturation product.

**Figure 3.** Survival of patients with non-cystic fibrosis bronchiectasis. (A) Survival in relation to BSI score, (B) Survival in relation to FACED score, (C) Survival in relation to DSP. BSI: bronchiectasis severity index; DSP: distance-saturation product.
reflects both exercise capacity and desaturation and was first introduced in predicting mortality in IPF patients [12]. Recently, Huang et al. showed that exertional desaturation during the 6MWT was a predictive factor for osteoporosis in NCFB patients [21]. In our previous research, we found that DSP predicted 6-year mortality in NCFB [13]. In the current analysis, we compared the BSI and FACED score with DSP in predicting mortality and demonstrated comparative results. The AUCs of overall mortality were 0.8 for BSI, 0.85 for FACED score, and 0.83 for DSP, similar to the previously reported AUCs of BSI and FACED score in other large study cohorts [6,7,22].

As mentioned above, the BSI played a complimentary role to the FACED score in predicting the exacerbation and hospitalization risk [23]. For better prediction for exacerbations in clinical practice, Mayor et al. proposed a modified version of FACED by adding previous exacerbations (Exa-FACED) and found that it could improve the AUC for exacerbations and hospitalizations [22]. Carrillo et al. further validated the Exa-FACED score in predicting all-cause mortality [24]. In the current study, both the BSI and FACED score were closely correlated with AE and admission. The BSI was associated with ED visit, although the FACED score was not. The DSP was only correlated with hospitalization and not AE and ED visit. This may be attributed to the fact that the DSP does not include previous exacerbation. However, with regard to mortality, the DSP demonstrated comparable predicting power as the BSI and FACED score. Introduction of the DSP in the context of these well-validate scores may increase the discriminatory power of BSI or FACED scores. Further large-scale, prospective studies are required.

Our study has some inherent limitations. First, it was a retrospective study, and we did not record quality of life (QoL) in the chart, therefore, we did not provide information about QoL. Second, DSP did not include previous AE and may have diminished the predicting power of AE, ED visit, and hospitalization. Moreover, clinic visit, ED visit, and hospitalization are relative accessible in Taiwan. This may have overestimated the BSI score and led to some bias. Fourth, our hospital was tertiary medical centre, the patients might have features of more severe bronchiectasis. Fifth, we couldn’t approach patients who look for another hospital while they developed AE. To validate the usefulness of the BSI score, FACED score, and DSP, cross-country, multicentre, large-scale, prospective studies are required.

Conclusions
DSP had comparable predictive power for mortality as the validated BSI and FACED scores and is relatively easy to use. Further cross-country studies are warranted to validate the usefulness and calculate the cut-off value of DSP in predicting mortality in NCFB patients.

Acknowledgements
The authors thank all the investigators and members of the Department of Thoracic Medicine for their efforts.

The abstract of this manuscript had been reported in poster Section in the 2020 Annual Congress of Taiwan Society of Pulmonary and Critical Care Medicine [25].

Ethics approval and consent to participate
This study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Review Committee of Chang Gung Medical Foundation (approval no. 201802305A3). The IRB of Chang Gung Medical Foundation waived the need to obtain consent for participation because of the retrospective nature of this study. All procedures followed were in accordance with the ethical standards of the IRB of Chang Gung Medical Foundation and with the Helsinki Declaration. All personal information was encrypted in a database, patient data were anonymised. No identifiable information, such as personal ID or birthday, were reported in this manuscript. There was no breach of privacy.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
This study was supported by research grants from the National Science Council of Taiwan [MOST 107-2314-B-182A-144]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability Statement and material
The data sets analysed during the current study are available from the corresponding author upon reasonable request.

References

[1] Hsieh MH, Chou PC, Chou CL, et al. Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan. PLoS One. 2013;8(6):e66265.

[2] Hsieh MH, Fang YF, Chen CY, Chung FT, et al. The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis. Pulm Med. 2013;2013:1–8.

[3] McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–656.

[4] Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.

[5] Martinez-Garcia MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–1367.

[6] McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven european cohorts. Thorax. 2016;71(12):1109–1118.

[7] Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J. 2016;47(2):482–489.

[8] Du H, Wonggom P, Tongpeth J, et al. Six-Minute walk test for assessing physical functional capacity in chronic heart failure. Curr Heart Fail Rep. 2017;14(3):158–166.

[9] Brown AW, Nathan SD. The value and application of the 6-Minute-Walk test in idiopathic pulmonary fibrosis. Am Am Thorac Soc. 2018;15(1):3–10.

[10] Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231–1237.

[11] Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-Minute walk test in bronchiectasis. Respir Med. 2009;103(5):780–785.

[12] Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100(10):1734–1741.

[13] Hsieh MH, Fang YF, Chung FT, et al. Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. J Thorac Dis. 2017;9(9):3168–3176.

[14] Wang H, Ji XB, Li CW, et al. Clinical characteristics and validation of bronchiectasis severity score systems for post-tuberculosis bronchiectasis. Clin Respir J. 2018;12(8):2346–2353.

[15] Hsieh MH, Lin CY, Wang CY, Fang YF, et al. Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis. Infect Drug Resist. 2018;11:1137–1143.

[16] ATS/CoP5fCPF L. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.

[17] Martin C, Chapron J, Hubert D, et al. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med. 2013;107(12):1881–1887.

[18] Miller MR, Hankinson J, Brusasco V, ATS/ERS Task Force, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.

[19] Andrianopoulos V, Wouters EF, Pinto-Plata VM, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir Med. 2015;109(9):1138–1146.

[20] Golpe R, Perez-de-Llano LA, Mendez-Marote L, et al. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6-minute walk test in COPD patients. Respir Care. 2013;58(8):1329–1334.

[21] Huang HY, Sheng TF, Lin CW, et al. Oxygen desaturation during the 6-min walk test as a risk for osteoporosis in non-cystic fibrosis bronchiectasis. BMC Pulm Med. 2019;19(1):28.

[22] Rosales-Mayor E, Polverino E, Raguer L, et al. Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS One. 2017;12(4):e0175171.

[23] Guan WJ, Chen RC, Zhong NS. The bronchiectasis severity index and FACED score for bronchiectasis. Eur Respir J. 2016;47(2):382–384.

[24] de la Rosa Carrillo D, Athanazio R, Giron Moreno RM, et al. The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis. ERJ Open Res. 2018;4(1):00139-2017.

[25] Ju J-S, Lin C-Y, Lin H-C. Predicting mortality in non-cystic fibrosis bronchiectasis patients using distance-saturation product. Poster Section (PC 52) in the 2020. Annual Congress of Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).